Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
about
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.Treatment of early onset schizophrenia: recent trends, challenges and future considerations.Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.Evaluation and treatment of children and adolescents with psychotic symptoms.Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine PractitionerTreatment of neurolept-induced tardive dyskinesiaAssociations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.Paliperidone extended release: in adolescents with schizophrenia.Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Development of novel therapy of schizophrenia in children and adolescents.The effect of antidepressants and antipsychotics on weight gain in children and adolescents.Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan.Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.Developmental effects of antipsychotic drugs on serotonin receptor subtypes.Early onset first episode psychosis: dimensional structure of symptoms, clinical subtypes and related neurodevelopmental markers.Association of viral hepatitis and bipolar disorder: a nationwide population-based study.
P2860
Q26747123-5DE54145-EFCB-403F-9EDC-30AA6B88E34CQ27003099-609836D8-83C2-4FA7-A027-3F25F3F43657Q33619940-F3CFFA9C-D512-4C3D-BB29-9C978AB56A3FQ34322230-E80142BF-63CF-48AD-8584-DA7F24B75956Q35370011-4159A3F4-1495-456F-83DC-1402D7C58674Q35816572-84E7DB4B-66F1-4BEB-9C8E-30341BE3301CQ35864793-569E6BD6-A2CF-464A-8273-60FA9907BD0AQ36233555-A3E9276F-D700-4242-8DAB-7B31BD8281A6Q36406640-CAE75A90-F547-44C1-B21B-9C2E7574DB5DQ36653419-DB15E0C0-911C-4E1F-8C0A-D91E2ECE54EEQ37198420-BB80C02A-925F-4D11-8391-AD8D9BF4895FQ37244634-EC6D4C37-469A-42E9-AF39-B9E71E656E12Q37244876-9C863EA0-F2AD-4E59-8FEF-965EC02B4C89Q38050832-6038C290-A156-4847-80B6-B12479A9FCA0Q38099224-E08C34A2-2BB2-48DB-A3FD-AA2CCEA4330CQ38223714-B792F1FF-CE8B-49F2-924E-956B9009F242Q38504263-5485DE55-660A-41C6-94C3-9DA24B110FDCQ38657158-B52D087F-0455-435F-B9EC-CF3FE04FF161Q39162868-5E15153D-6490-41A1-986F-F5B6C4011639Q39422983-D16A77DA-6C75-4CD8-AB0C-2B2E87C802FAQ41495591-E08EFA04-5BD6-483A-9EC2-D0E6C8DDEB9DQ48301821-C7563247-6EB4-44E7-9D5D-D46767AB1EC3Q53140207-ADCCB25B-9CEE-40D7-825A-F2833AB98F6DQ55443448-7ECF86C5-8B4A-43E9-819E-87027A972CB7
P2860
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@en
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@nl
type
label
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@en
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@nl
prefLabel
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@en
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@nl
P2860
P921
P1433
P1476
Management of schizophrenia in children and adolescents: focus on pharmacotherapy.
@en
P2093
Francesca Liboni
P2860
P304
P356
10.2165/11585350-000000000-00000
P577
2011-01-01T00:00:00Z
P6179
1009768672